Advanced search
1 file | 682.82 KB

Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis

Author
Organization
Abstract
The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 mu g/day) (ABL) for 18months followed by 6months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with an osteoanabolic agent. The ABL/ALN sequence resulted in greater bone mineral density gains at all skeletal sites and in a reduction of vertebral, non-vertebral, major and clinical fractures compared to what is observed after 18months of placebo followed by 6months of ALN. Whereas questions remained unanswered about the ideal anti-resorptive agent to be used after ABL, the optimal duration of the administration of the anti-resorptive drug or the potential interest of re-initiating a course of ABL after a limited administration of ALN, these results support the use of the ABL/ALN sequence in the management of postmenopausal osteoporosis.
Keywords
Abaloparatide, osteoporosis, bisphosphonates, sequential treatment, fractures, WOMEN, TRIAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 682.82 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Reginster, JY, Nasser Al Daghri, Jean Kaufman, and Olivier Bruyere. 2018. “Effect of a Sequential Treatment Combining Abaloparatide and Alendronate for the Management of Postmenopausal Osteoporosis.” Expert Opinion on Pharmacotherapy 19 (2): 159–161.
APA
Reginster, J., Al Daghri, N., Kaufman, J., & Bruyere, O. (2018). Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. EXPERT OPINION ON PHARMACOTHERAPY, 19(2), 159–161.
Vancouver
1.
Reginster J, Al Daghri N, Kaufman J, Bruyere O. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. EXPERT OPINION ON PHARMACOTHERAPY. 2018;19(2):159–61.
MLA
Reginster, JY et al. “Effect of a Sequential Treatment Combining Abaloparatide and Alendronate for the Management of Postmenopausal Osteoporosis.” EXPERT OPINION ON PHARMACOTHERAPY 19.2 (2018): 159–161. Print.
@article{8607982,
  abstract     = {The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 mu g/day) (ABL) for 18months followed by 6months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with an osteoanabolic agent. The ABL/ALN sequence resulted in greater bone mineral density gains at all skeletal sites and in a reduction of vertebral, non-vertebral, major and clinical fractures compared to what is observed after 18months of placebo followed by 6months of ALN. Whereas questions remained unanswered about the ideal anti-resorptive agent to be used after ABL, the optimal duration of the administration of the anti-resorptive drug or the potential interest of re-initiating a course of ABL after a limited administration of ALN, these results support the use of the ABL/ALN sequence in the management of postmenopausal osteoporosis.},
  author       = {Reginster, JY and Al Daghri, Nasser and Kaufman, Jean and Bruyere, Olivier},
  issn         = {1465-6566},
  journal      = {EXPERT OPINION ON PHARMACOTHERAPY},
  keywords     = {Abaloparatide,osteoporosis,bisphosphonates,sequential treatment,fractures,WOMEN,TRIAL},
  language     = {eng},
  number       = {2},
  pages        = {159--161},
  title        = {Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis},
  url          = {http://dx.doi.org/10.1080/14656566.2017.1418857},
  volume       = {19},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: